
## Krista L Dobo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10085025/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product <i>N</i> -Nitrosamine Impurities. Chemical Research in Toxicology, 2022, 35, 475-489.	3.3	36
2	Management of pharmaceutical ICH M7 (Q)SAR predictions – The impact of model updates. Regulatory Toxicology and Pharmacology, 2020, 118, 104807.	2.7	15
3	2â€Hydroxypyridine Nâ€Oxide is not genotoxic in vivo. Environmental and Molecular Mutagenesis, 2019, 60, 588-593.	2.2	2
4	Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses. Regulatory Toxicology and Pharmacology, 2019, 102, 53-64.	2.7	21
5	2â€Hydroxypyridineâ€Nâ€oxide (HOPO): Equivocal in the ames assay. Environmental and Molecular Mutagenesis, 2018, 59, 312-321.	2.2	2
6	In silico toxicology protocols. Regulatory Toxicology and Pharmacology, 2018, 96, 1-17.	2.7	159
7	Resolution of contradiction between in silico predictions and Ames test results for four pharmaceutically relevant impurities. Regulatory Toxicology and Pharmacology, 2017, 91, 68-76.	2.7	8
8	Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses. Regulatory Toxicology and Pharmacology, 2016, 77, 13-24.	2.7	83
9	Evaluation of the in vivo mutagenicity of isopropyl methanesulfonate in acute and 28â€day studies. Environmental and Molecular Mutagenesis, 2015, 56, 322-332.	2.2	7
10	A practical application of two in silico systems for identification of potentially mutagenic impurities. Regulatory Toxicology and Pharmacology, 2015, 72, 335-349.	2.7	43
11	Compensatory erythropoiesis has no impact on the outcome of the in vivo Pig-a mutation assay in rats following treatment with the haemolytic agent 2-butoxyethanol. Mutagenesis, 2015, 30, 325-334.	2.6	15
12	Establishing best practise in the application of expert review of mutagenicity under ICH M7. Regulatory Toxicology and Pharmacology, 2015, 73, 367-377.	2.7	70
13	Evaluation of the <i>Pigâ€a</i> , micronucleus, and comet assay endpoints in a 28â€day study with ethyl methanesulfonate. Environmental and Molecular Mutagenesis, 2014, 55, 492-499.	2.2	8
14	Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. Regulatory Toxicology and Pharmacology, 2013, 67, 39-52.	2.7	105
15	Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis. Regulatory Toxicology and Pharmacology, 2013, 65, 201-213.	2.7	7
16	In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry survey. Regulatory Toxicology and Pharmacology, 2012, 62, 449-455.	2.7	75
17	Defining EMS and ENU dose–response relationships using the Pig-a mutation assay in rats. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2011, 725, 13-21.	1.7	46
18	Report on stage III <i>Pigâ€a</i> mutation assays using <i>N</i> â€ethylâ€ <i>N</i> â€nitrosourea – comparison with other in vivo genotoxicity endpoints. Environmental and Molecular Mutagenesis, 2011, 52, 721-730.	<sup>1</sup> 2.2	38

Krista L Dobo

#	Article	IF	CITATIONS
19	A Strategy for the Risk Assessment of Human Genotoxic Metabolites. Chemical Research in Toxicology, 2009, 22, 348-356.	3.3	27
20	Overview of Genotoxic Impurities in Pharmaceutical Development. International Journal of Toxicology, 2009, 28, 468-478.	1.2	28
21	An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities. Regulatory Toxicology and Pharmacology, 2007, 48, 75-86.	2.7	45
22	The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. Regulatory Toxicology and Pharmacology, 2006, 44, 282-293.	2.7	106